Resbiotic Nutrition, Inc., a physician-scientist-founded health and wellness company specializing in microbiome-based products, recently concluded an $8 million Series A funding round supported by major shareholders Sororibus Capital and Biostack Ventures. This brings the total funds the company has raised to $14.5 million.

The new funding will be used to expand the company’s product portfolio, scale retail and ecommerce distribution, and strengthen its B2B ingredient and formulations business, the company said.

Resbiotic is pioneering the “Gut-X Axis,” a science-driven platform that connects gut health to whole-body outcomes across multiple systems, to address chronic health struggles.

The company’s flagship product, resB Lung Support, claims to be the first clinically tested probiotic targeting the gut-lung axis for respiratory health. Building on this foundation, Resbiotic is now extending its platform into metabolic health, women’s health, and bone health, addressing consumer concerns with clinically validated solutions.

“With res, we are setting a new standard in the supplement industry — products that are not only rooted in rigorous science but also accessible to people everywhere,” said Dr. C. Vivek Lal, founder and CEO. “By combining robust preclinical testing and clinical trials at the product level with a vertically integrated R&D model, we ensure our formulations deliver real, measurable benefits. This funding enables us to expand our Gut-X Axis portfolio, deepen our retail partnerships, and meet growing consumer demand for evidence-based health solutions.”

Alongside its consumer offerings, the company’s B2B division is experiencing growth, driven by demand for its proprietary formulations and novel microbiome-based ingredients. 

Resbiotic products are now available through Walmart stores nationwide and the company’s direct-to-consumer ecommerce platform.